Bristol Myers Squibb Terminates Immatics’ Bispecific Collaboration

Monday, 16 September 2024, 03:59

Bristol Myers Squibb has axed another cancer candidate from its pipeline, having initially invested $150 million in Immatics’ bispecific project. This decision adds to a series of terminations stemming from strategic re-evaluations under the company’s previous leadership. Immatics now retains full control over the bispecific candidate.
LivaRava_Medicine_Default.png
Bristol Myers Squibb Terminates Immatics’ Bispecific Collaboration

Bristol Myers Squibb's Strategic Shift

Bristol Myers Squibb, a major player in oncology, has made a pivotal decision by terminating its partnership with Immatics. This collaboration was originally established with a significant investment of $150 million, aimed at advancing cancer treatment through bispecific technologies.

Details of the Termination

  • Immatics now gains full rights over the bispecific candidate previously intertwined with Bristol Myers Squibb.
  • This move reflects a broader trend within the company to streamline its oncology pipeline.
  • The decision has been influenced by shifting priorities and a reassessment of current projects.

Implications for the Oncology Landscape

This termination signifies more than just a partnership dissolution; it underlines the competitive nature of oncology research and development. Immatics is expected to pivot towards alternative funding options to advance its bispecific strategies independently.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe